Insmed Incorporated - Common Stock (NQ:INSM)

93.39 -1.67 (-1.76%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insmed Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026

March 09, 2026

As of March 9, 2026, a dramatic regime shift is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and AI-driven mega-caps, small-cap stocks have emerged as the...

Via MarketMinute

Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗

March 03, 2026

PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Via The Motley Fool

Topics Regulatory Compliance

Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗

March 02, 2026

This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets.

Via The Motley Fool

Topics Regulatory Compliance

Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year ↗

February 23, 2026

Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗

February 23, 2026

GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.

Via The Motley Fool

Topics Regulatory Compliance

Insmed (INSM) Q4 2025 Earnings Call Transcript ↗

February 19, 2026

Insmed (INSM) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma.

Via The Motley Fool

Topics Regulatory Compliance

Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗

February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.

Via The Motley Fool

Topics Regulatory Compliance

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress ↗

February 14, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, with candidates targeting depression and epilepsy.

Via The Motley Fool

Topics Regulatory Compliance

Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million ↗

February 14, 2026

This clinical-stage biotech develops monoclonal antibody therapies targeting chronic inflammatory and immunological diseases.

Via The Motley Fool

Topics Regulatory Compliance

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib ↗

January 06, 2026

Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.

Via The Motley Fool

Topics Stocks

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm

December 29, 2025

From The Schall Law Firm

Via Business Wire

Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗

December 28, 2025

Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.

Via The Motley Fool

Topics Regulatory Compliance

Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗

December 17, 2025

While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg.

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

December 17, 2025

As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an...

Via MarketMinute

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

December 02, 2025

From BioMedWire

Via GlobeNewswire

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks ↗

November 30, 2025

Stanley Druckenmiller is considered one of the greatest investors of all time.

Via The Motley Fool

Topics Artificial Intelligence

Billionaire Stanley Druckenmiller Just Bet Big on This Hot IPO Stock. Is It a Buy? ↗

November 23, 2025

This online ticket marketplace debuted in September, but has struggled thus far.

Via The Motley Fool

Topics ETFs Initial Public Offering Regulatory Compliance

Peering Into Insmed Inc's Recent Short Interest ↗

November 18, 2025

Via Benzinga

Druckenmiller Opens Position In Amazon, Closes Microsoft — Here's More Of Duquesne's Biggest Q3 Moves ↗

November 14, 2025

Stanley Druckenmiller's Duquesne Family Office Q3 13F reinforces the firm's reputation for agile and opportunity-driven asset allocation.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.